LANREOTIDE BACHEM

The long-acting somatostatin agonist **Lanreotide** (INN) was initially developed for the management of acromegaly, for which it has been approved in many countries. Consecutive studies showed that lanreotide alleviates symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome, and can serve as an alternative to octreotide in this field. Interestingly, lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogs, is being studied as a possible general anti-tumor agent.

Its anti-cancer activities turn lanreotide into a promising drug candidate and leave much room for the development of new indications and optimization of formulations. The peptide drug is usually administered as prolonged-release formulation.

A recent multinational clinical phase III study showed the anti-proliferative effect of sustained-release lanreotide on metastatic gastroenteropancreatic neuroendocrine tumors resulted in a substantial delay of tumor progression (Caplin, M. E. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 371, 224-233 (2014); Clin. Adv. Hematol. Oncol. 14 (5 Suppl 7), 6-7 (2016)).

Bachem, the world's leading manufacturer of peptide active pharmaceutical ingredients, is your reliable source for lanreotide and other somatostatin agonists.

Lanreotide

H-9055-GMP

Sequence: H-D-2-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂ (Disulfide bond)

CAS-Number: 108736-35-2 (net), 127984-74-1 (acetate)

 $\begin{array}{l} {\rm Molecular\,Formula:\,C_{54}H_{69}N_{11}O_{10}S_2} \\ {\rm Molecular\,Weight\,1096.34\,g/mol} \end{array}$

Bachem is your trusted partner through all phases of drug development

Preclinical phase ■ Material for research purposes (non-GMP and GMP) ✓ Already available

Clinical phases Synthesis of the required GMP material including documentation CMC phase I-III, DMF Development and validation of analytical methods

Market supply Large-scale production for product launch

Stability studies
Commitment to our partners and projects

BACHEM

Generic APIs from Bachem

✓ Quality

- · GMP and non-GMP quality
- Broad range of impurities & related products
- · State of the art analytical capabilities
- ISO 13485 certified manufacturing site in St. Helens, UK

✓ Capacity

- · Production sites in the USA and Europe
- · Largest production facilities in the market
- Up-to-date technology

✓ Support

- · Highly qualified technical support team
- Documentation
- Confidentiality
- · Industry leader and pioneering partner

The Swiss based Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of pepTides and oligonucleoTides. As a full service provider Bachem offers products for clinical development and commercial applications as well as a comprehensive catalog and exclusive custom synthesis. With 50 years of experience and subsidiaries in Switzerland, the United States, the United Kingdom and Japan, Bachem is the partner of choice for the biotech and pharma industry worldwide.

Bachem. Leading Partner in Tides

Marketing & Sales Contact

America

Bachem Americas, Inc.

Tel. +1 888 422 2436 (toll free in USA & Canada)

+1 310 539 4171

sales.us@bachem.com

Asia Pacific

Bachem Japan K.K.

Tel. +81 3 6661 0774 sales.jp@bachem.com

Europe, Africa, Middle East and India

Bachem AG

Tel. +41 58 595 2020 sales.ch@bachem.con

Visit our website www.bachem.com or shop online shop.bachem.com

All information is compiled to the best of our knowledge. We cannot be made liable for any possible errors or misprints. Some products may be restricted in certain countries.







shop.bachem.com